Scott Wilkinson Sells 30,651 Shares of Inogen Inc (INGN) Stock
Inogen Inc (NASDAQ:INGN) insider Scott Wilkinson sold 30,651 shares of the company’s stock in a transaction dated Tuesday, January 16th. The stock was sold at an average price of $115.75, for a total transaction of $3,547,853.25. Following the completion of the sale, the insider now directly owns 38,107 shares in the company, valued at approximately $4,410,885.25. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink.
Shares of Inogen Inc (INGN) traded down $0.96 during midday trading on Friday, reaching $114.99. 99,500 shares of the company traded hands, compared to its average volume of 174,217. The firm has a market cap of $2,380.00, a P/E ratio of 80.41, a price-to-earnings-growth ratio of 3.93 and a beta of 1.13. Inogen Inc has a 1-year low of $62.69 and a 1-year high of $130.05.
Inogen (NASDAQ:INGN) last issued its quarterly earnings results on Tuesday, November 7th. The medical technology company reported $0.33 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.29 by $0.04. The business had revenue of $69.00 million for the quarter, compared to the consensus estimate of $63.55 million. Inogen had a net margin of 11.36% and a return on equity of 13.37%. The firm’s quarterly revenue was up 26.8% on a year-over-year basis. During the same quarter in the prior year, the company earned $0.25 EPS. analysts predict that Inogen Inc will post 1.19 EPS for the current year.
Hedge funds and other institutional investors have recently modified their holdings of the stock. Piedmont Investment Advisors LLC acquired a new position in Inogen during the 2nd quarter worth about $336,000. Parametric Portfolio Associates LLC lifted its position in Inogen by 63.6% during the 2nd quarter. Parametric Portfolio Associates LLC now owns 45,969 shares of the medical technology company’s stock worth $4,386,000 after buying an additional 17,867 shares in the last quarter. Vanguard Group Inc. lifted its position in Inogen by 24.9% during the 2nd quarter. Vanguard Group Inc. now owns 1,515,342 shares of the medical technology company’s stock worth $144,594,000 after buying an additional 301,737 shares in the last quarter. Koch Industries Inc. lifted its position in Inogen by 19,485.8% during the 2nd quarter. Koch Industries Inc. now owns 657,102 shares of the medical technology company’s stock worth $650,000 after buying an additional 653,747 shares in the last quarter. Finally, BlackRock Inc. lifted its position in Inogen by 1.9% during the 2nd quarter. BlackRock Inc. now owns 2,150,552 shares of the medical technology company’s stock worth $205,207,000 after buying an additional 39,752 shares in the last quarter.
Inogen Company Profile
Inogen, Inc is a medical technology company. The Company develops, manufactures and markets portable oxygen concentrators used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions. The Company’s Inogen One systems concentrate the air around the patient to offer a single source of supplemental oxygen anytime, anywhere with a portable device.
Receive News & Ratings for Inogen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inogen and related companies with MarketBeat.com's FREE daily email newsletter.